Reena Pabari

Dr. Reena Pabari

The Hospital for Sick Children, Toronto, Ontario, Canada
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2022 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
Reena PabariReena Pabari
Reena Pabari
KCKathy PhD Chun
Kathy PhD Chun
ANAhmed Mbbs Naqvi
Ahmed Mbbs Naqvi
Juvenile myelomonocytic leukemia (JMML) is a rare, aggressive pediatric disorder characterized by pathologic myeloproliferation because of alterations in RAS pathway genes. NRAS-mutated JMML encompasses a broad range of clinical severity. Herein we describe 4 unique cases of NRAS-mutated JMML and JMML-like myeloproliferation, 2 with somatic mutations and 2 with germline mutations. These cases illustrate the diverse clinical and hematologic presentation of this subtype of JMML, including a very unusual example presenting with Auer rods. Lastly, this is the first report of patients with phenotypic Costello syndrome presenting with JMML-like myeloproliferation, highlighting an important clinical phenomenon that has not been previously described.

4 August 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
FHFyeza Hasan
Fyeza Hasan
Reena PabariReena Pabari
Reena Pabari
MWMarta Wilejto
Marta Wilejto
Pediatric oncologists have the privilege of caring for children and families facing serious, often life-threatening, illnesses. Providing this care is emotionally demanding and associated with significant risks of stress and burnout for oncologists. Traditional approaches to physician burnout and wellbeing have not emphasized the potential roles of education and training in mitigating this stress. In this commentary, we discuss the contribution that education, particularly in the areas of palliative and psychosocial oncology, can make in preparing oncologists for the work that they do. We argue that by adequately providing oncologists with the skills they need for their work, we can reduce their risk of burning out. We also discuss the importance of paying attention to hidden and formal curricula to ensure that messages provided in formal education programs are supported by informal training experiences.

20 September 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JPJessica A. Pollard
Jessica A. Pollard
TATodd A. Alonzo
Todd A. Alonzo
RGRobert B. Gerbing
Robert B. Gerbing
MKMatthew Kutny
Matthew Kutny
BHBetsy Hirsch
Betsy Hirsch
TCTodd M Cooper
Todd M Cooper
PURPOSE: The Children's Oncology Group phase III clinical trial AAML1831 (ClinicalTrials.gov identifier: NCT04293562 ) evaluated liposomal daunorubicin and cytarabine (CPX-351) versus standard daunorubicin/cytarabine (DA) induction therapy in children and young adults with newly diagnosed AML. We hypothesized that CPX-351 given during induction 1 and 2 would improve outcomes compared with DA. PATIENTS AND METHODS: Patients (21 years and younger) were randomly assigned to two cycles of DA induction (arm A = DA) or CPX-351 (arm B = CPX-351). All patients also received gemtuzumab ozogamicin in induction 1. Postinduction chemotherapy was according to risk assignment made at the end of induction 1 (EOI1). Those with high-risk (HR) AML received consolidation with allogeneic hematopoietic stem-cell transplantation (HSCT), whereas low-risk (LR) patients received chemotherapy alone. Protocol-specified interim analysis monitored efficacy and futility of CPX-351 induction with respect to the primary end point, event-free survival (EFS) from study entry. Disease-free survival (DFS) was calculated to determine the impact of EOI1 risk assignment. RESULTS: Seven hundred twenty-one eligible patients with FLT3 wild-type AML were randomly assigned to DA (n = 358) or CPX-351 (n = 363). Interim analysis determined that the futility monitoring rule was crossed because of inferior EFS in the CPX-351 arm and the random assignment was stopped. The two-year EFS from study entry was 62.2% for DA versus 51.2% for CPX-351 ( P = .011). DFS for patients with HR AML was comparable for both arms. However, DFS was significantly lower and cumulative incidence of relapse (CIR) was higher for LR patients assigned to CPX-351 versus DA (2-year DFS from EOI1: DA: 73.8% v CPX-351 57.5% [ P = .001]; 2-year CIR Arm DA: 23.6% v CPX-351: 39.9% [ P = .001]). CONCLUSION: CPX-351 was inferior to DA induction in the AAML1831 trial with differential EFS largely driven by events in LR patients.

13 September 2024 in Blood Advances
Verified
Journal Article
Open access
Reena PabariReena Pabari
Reena Pabari
KMKathleen McCarten
Kathleen McCarten
JFJamie Flerlage
Jamie Flerlage
HLHollie Lai
Hollie Lai
CMChristine Mauz-Koerholz
Christine Mauz-Koerholz
LKLars Kurch
Lars Kurch
Hodgkin lymphoma (HL) involving the central nervous system (CNS) is exceedingly rare. Information regarding the presentation, management, treatment, and outcome of patients with CNS HL is limited to case reports or small series. We describe 45 pediatric patients with 55 extra-axial CNS lesions at diagnosis with HL from a cohort of 4995 patients enrolled on Children’s Oncology Group AHOD1331 and the European Network for Pediatric Hodgkin lymphoma C1 and C2 trials, with an overall incidence of 0.9%. Up to 82.2% of patients had a single CNS lesion in the thoracic, lumbar, or sacral spine. In the evaluated cohort, HL did not occur within the CNS parenchyma. Lesions extended into the extra-axial CNS space from adjacent soft tissue or bone and never directly infiltrated through the dura into the brain or spinal cord. Patients with CNS involvement had a twofold greater incidence of extranodal lesions than previously reported cohorts without CNS involvement. After 2 cycles of chemotherapy, 89.1% of CNS lesions demonstrated a complete metabolic response and >75% decrease in volume. Thirteen CNS lesions (23.6%) received irradiation; none were sites of disease relapse. Relapse occurred at the site of 2 lesions involving the CNS, both of which had an adequate interim response to chemotherapy. In summary, we present, to our knowledge, the largest reported cohort of systemic HL involving the CNS at diagnosis, demonstrating that these lesions originate from surrounding tissues, extend into the extra-axial CNS space, and respond similarly to other nodal and extranodal disease. The trials were registered at www.clinicaltrials.gov as #NCT02166463, #NCT00433459, and #NCT02684708.


20 August 2026 in Paediatrics & Child Health
Verified
Journal Article
Closed access
RZRachelle Zipper
Rachelle Zipper
CCClarisse Carcao
Clarisse Carcao
MMMaggie McNeill
Maggie McNeill
HSHannah Shier
Hannah Shier
NINethmi Illamperuma
Nethmi Illamperuma
MCManuel Carcao
Manuel Carcao
Introduction: Excessive cow's milk intake is a leading cause of iron deficiency (ID) and anaemia in toddlers. We sought to describe the complications of very severe ID anaemia (vsIDA) in children presenting to the largest tertiary paediatric hospital in Canada. Methods: This retrospective review included otherwise healthy children aged 0 to 5 years with haemoglobin (Hb) ≤ 50 g/L and ≥1 ID-specific marker (presenting 01/2020 to 12/2024). The primary objective was to analyze vsIDA-related complications; secondary objectives were to describe interventions received and identify risk factors for developing vsIDA (e.g., cow's milk intake, bottle use). Results: We identified 128 children with vsIDA, with a median age of 23 months and a median Hb of 38 g/L (12 to 50 g/L). Most children (84%) drank >500 mL/day of cow's milk; 91% of those ≥12 months old used a bottle. Excessive milk intake tended to be associated with lower Hb (P = 0.058); bottle use strongly correlated with excessive milk intake (P = 0.005). Of the 128 children, 57.8% were hospitalized, 47.7% received ≥1 red blood cell transfusion, and 21.1% received ≥1 iron infusion. Complications included developmental delay (28.1%), abnormal echocardiograms (11 of 13 performed, 85%), thrombotic events (n = 4; cerebral sinus venous thrombosis [CSVT] and/or deep vein thrombosis), and death (n = 2, one from cardiac failure and CSVT/stroke, the other from cardiac arrest). Conclusions: Significant morbidity and mortality can occur with vsIDA in otherwise healthy children, including developmental delay, heart failure, strokes, and death. These complications can be avoided with improved education, screening, dietary counselling, and removing bottles from children >12 to 18 months old.